Multi-center, Randomized, Open-labeled, Positive-controlled, Phase II Study to Evaluate Efficacy and Safety of YPEG-rhG-CSF, Once-per-cycle, Comparing to PEG-rhG-CSF, Once-per-cycle, in Chemotherapy-induced Neutropenia of Patients With Malignancies Receiving Myelosuppressive Chemotherapy.

Trial Profile

Multi-center, Randomized, Open-labeled, Positive-controlled, Phase II Study to Evaluate Efficacy and Safety of YPEG-rhG-CSF, Once-per-cycle, Comparing to PEG-rhG-CSF, Once-per-cycle, in Chemotherapy-induced Neutropenia of Patients With Malignancies Receiving Myelosuppressive Chemotherapy.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Pegfilgrastim (Primary)
  • Indications Neutropenia
  • Focus Therapeutic Use
  • Sponsors Xiamen Amoytop Biotech
  • Most Recent Events

    • 28 Mar 2017 Planned End Date changed from 1 Dec 2017 to 1 Oct 2017.
    • 28 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 20 Jun 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top